|
|
Volumn 97, Issue 7, 2005, Pages 473-
|
|
FDA oncology committee debate's Iressa's status following negative trial results
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ERLOTINIB;
GEFITINIB;
PLACEBO;
ANTINEOPLASTIC AGENT;
QUINAZOLINE DERIVATIVE;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
CLINICAL TRIAL;
DATA ANALYSIS;
DRUG APPROVAL;
DRUG COST;
DRUG LABELING;
DRUG PACKAGING;
DRUG RESPONSE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LUNG CANCER;
LUNG NON SMALL CELL CANCER;
NOTE;
PRIORITY JOURNAL;
SIDE EFFECT;
UNITED STATES;
ARTICLE;
LUNG TUMOR;
TREATMENT FAILURE;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
DRUG APPROVAL;
HUMANS;
LUNG NEOPLASMS;
QUINAZOLINES;
TREATMENT FAILURE;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 15944380406
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/97.7.473 Document Type: Note |
|
Times cited : (12)
|
|
References (0)
|